Royal Bank Of Canada Arcutis Biotherapeutics, Inc. Transaction History
Royal Bank Of Canada
- $471 Billion
- Q3 2024
A detailed history of Royal Bank Of Canada transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 12,246 shares of ARQT stock, worth $164,096. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,246
Previous 12,653
3.22%
Holding current value
$164,096
Previous $117,000
3.42%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding ARQT
# of Institutions
197Shares Held
129MCall Options Held
738KPut Options Held
82K-
Jennison Associates LLC11.7MShares$156 Million0.07% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$147 Million2.84% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.7MShares$144 Million3.92% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$118 Million4.4% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$116 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $807M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...